TickerHumSide-by-side comparison
Moderna vs Pfizer
As of Nov 11, 2026, P/S is 39.9x for Moderna vs 2.6x for Pfizer; revenue growth is 13.1% for Moderna vs 1.3% for Pfizer; net margin is -110.5% for Moderna vs 6.3% for Pfizer; debt/equity is 0.09 for Moderna vs 0.67 for Pfizer.
What stands out
- Moderna is growing revenue faster: 13.1% vs 1.3% for Pfizer.
- Moderna carries less debt relative to equity: 0.09 vs 0.67 for Pfizer.
- Moderna's shares did better over the past year: +831.1% vs +13.8% for Pfizer.
Key metrics
| Metric | MRNA | PFE |
|---|---|---|
| Price | $248.69 | $29.45 |
| Market cap | $100.63B | $167.86B |
| P/E | — | 42.1x (#1) |
| P/S | 39.9x (#2) | 2.6x (#1) |
| Revenue growth | 13.1% (#1) | 1.3% (#2) |
| Operating margin | -116.0% (#1) | — |
| Net margin | -110.5% (#2) | 6.3% (#1) |
| Debt / equity | 0.09 (#1) | 0.67 (#2) |
| 1-year return | +831.1% (#1) | +13.8% (#2) |
| Research score | 47/100 (#2) | 51/100 (#1) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Moderna, Inc. (MRNA) — Biotechnology
- Pfizer Inc. (PFE) — Drug Manufacturers—General